Kuwait vs Kyrgyzstan: Access to anti-retroviral drugs, female
Kuwait
58.0%
in 2024
Kyrgyzstan
60.0%
in 2024
Kuwait rank
105th
Kyrgyzstan rank
103rd
Access to anti-retroviral drugs, female over time
- Kuwait
- Kyrgyzstan
How they compare
Kyrgyzstan currently reports 60.0% against 58.0% in Kuwait, a difference of 2.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Kuwait ahead.
Kuwait ranks 105th and Kyrgyzstan ranks 103rd of 141 countries.
Across the 3 decades both report, Kuwait averaged higher in 2 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Kuwait | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 24.2% | 0.7% | 23.5% | Kuwait |
| 2010s | 33.3% | 26.4% | 6.9% | Kuwait |
| 2020s | 51.6% | 54.8% | 3.2% | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Kuwait or Kyrgyzstan?
- Kyrgyzstan, at 60.0% against 58.0% in Kuwait as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Kuwait and Kyrgyzstan?
- 2.0%, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kuwait and Kyrgyzstan?
- 25 years are reported by both, from 2000 to 2024.
- How do Kuwait and Kyrgyzstan rank globally for access to anti-retroviral drugs, female?
- Kuwait ranks 105th and Kyrgyzstan ranks 103rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.